Alkermes PLC (ALKS)
Stock Price:
$18.56 USD
-0.15 (-0.78%)
Updated Aug 10, 2020 2:15 PM EDT - Market open
Key Info
| Market Cap |
2.95B |
| Revenue (ttm) |
1.16B |
| Net Income (ttm) |
-126.32M |
| Shares Out |
159.04M |
| EPS (ttm) |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
156.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$18.56 |
| Previous Close |
$18.70 |
| Change ($) |
-0.15 |
| Change (%) |
-0.78% |
| Day's Open |
18.77 |
| Day's Range |
18.14 - 18.77 |
| Day's Volume |
445,348 |
| 52-Week Range |
11.98 - 23.22 |
More Stats
| Market Cap |
2.95B |
| Enterprise Value |
2.81B |
| Earnings Date (est) |
Oct 21, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
159.04M |
| Float |
157.34M |
| EPS (basic) |
-0.8 |
| EPS (diluted) |
-0.80 |
| FCF / Share |
-0.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
11.92M |
| Short Ratio |
6.44 |
| Short % of Float |
9.40% |
| Beta |
1.43 |
| PE Ratio |
n/a |
| Forward PE |
156.25 |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.54 |
| PB Ratio |
2.79 |
| Revenue |
1.16B |
| Operating Income |
-134.59M |
| Net Income |
-126.32M |
| Free Cash Flow |
-52.82M |
| Net Cash |
141.78M |
| Net Cash / Share |
0.89 |
| Gross Margin |
85.27% |
| Operating Margin |
-11.59% |
| Profit Margin |
-10.90% |
| FCF Margin |
-4.55% |
| ROA |
-4.26% |
| ROE |
-11.73% |
| ROIC |
-7.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (12)
| Buy |
1 |
| Overweight |
0 |
| Hold |
10 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$19.64*
(5.85% upside)
Low
15.0
Current: $18.56
High
26.0
Target: 19.64
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 |
|---|
| Revenue | 1,171 | 1,094 | 903 | 746 | 628 | 619 | 576 | 390 | 187 | 178 |
| Revenue Growth | 7.01% | 21.13% | 21.15% | 18.68% | 1.54% | 7.51% | 47.59% | 108.95% | 4.69% | - |
| Gross Profit | 991 | 918 | 749 | 614 | 489 | 443 | 405 | 262 | 134 | 129 |
| Operating Income | -175 | -99.13 | -148 | -209 | -224 | -87.14 | 81.81 | -88.28 | -45.63 | -43.03 |
| Net Income | -197 | -139 | -158 | -208 | -227 | -30.06 | 24.98 | -114 | -45.54 | -39.63 |
| Shares Outstanding | 157 | 155 | 153 | 151 | 149 | 145 | 132 | 115 | 95.61 | 94.84 |
| Earnings Per Share | -1.25 | -0.90 | -1.03 | -1.38 | -1.52 | -0.21 | 0.18 | -0.99 | -0.48 | -0.42 |
| Operating Cash Flow | 72.08 | 99.28 | 19.19 | -63.80 | -40.36 | 11.14 | 127 | -2.48 | -5.91 | -12.25 |
| Capital Expenditures | -90.04 | -68.92 | -51.14 | -43.46 | -52.34 | 10.71 | -22.02 | -16.95 | -9.01 | -15.54 |
| Free Cash Flow | -17.97 | 30.36 | -31.95 | -107 | -92.70 | 21.85 | 105 | -19.44 | -14.91 | -27.79 |
| Cash & Equivalents | 535 | 539 | 434 | 497 | 535 | 631 | 221 | 190 | 201 | 281 |
| Total Debt | 291 | 279 | 281 | 284 | 350 | 356 | 369 | 444 | - | 51.04 |
| Net Cash / Debt | 244 | 260 | 152 | 214 | 185 | 275 | -148 | -254 | 201 | 230 |
| Assets | 1,805 | 1,825 | 1,797 | 1,726 | 1,856 | 1,919 | 1,470 | 1,435 | 452 | 516 |
| Liabilities | 720 | 654 | 594 | 517 | 541 | 522 | 518 | 581 | 60.43 | 103 |
| Book Value | 1,085 | 1,171 | 1,203 | 1,209 | 1,314 | 1,397 | 952 | 854 | 392 | 413 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Alkermes PLC |
| Country |
Ireland |
| Employees |
2,235 |
| CEO |
Richard F. Pops |
Stock Information
| Ticker Symbol |
ALKS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALKS |
| IPO Date |
July 16, 1991 |
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.